The Latest Breaking News from GILD

The COVID-19 pandemic caused immense volatility in the stock market, further aggravated by high inflation and consecutive rate hikes by the Fed. Amid the uncertainties, healthcare stocks tend to provide some hedge. We think COVID-19 darlings Pfizer (PFE) and Gilead Sciences (GILD) are still worth buying. Continue reading.

The stock market volatility is not expected to end anytime soon as the macroeconomic headwinds remain. So, I think fundamentally solid Johnson & Johnson (JNJ), Gilead Sciences (GILD), Stellantis (STLA), and Cardinal Health (CAH) could be the best stocks to own now and forever. Keep reading.

Despite showing signs of cooling, inflation is still well above the Fed’s 2% target. Moreover, January’s strong jobs report may encourage the Fed to raise interest rates even further, keeping the stock market highly volatile in the near term. Amid an uncertain macro environment, it could be wise to buy…

With the market relapsing into a fresh bout of the volatility after estimate-crushing employment numbers, high dividend-yielding and fundamentally sound stock Gilead Sciences (GILD) could help investors secure a steady income stream. Read on….

January’s robust job report is raising concerns about how long the Fed will keep interest rates high. Market experts are now expecting a higher terminal interest rate. As uncertainty clouds over, quality stocks Gilead Sciences (GILD), Valero Energy (VLO), and ARC Document (ARC) that pay stable dividends might be ideal…

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

Despite an inflow of positive macro data, the Fed’s hawkish stance is expected to keep the markets under pressure for the near term. With price fluctuations being the new norm, dividend-paying stocks with solid fundamentals, BHP Group (BHP) and Gilead Sciences (GILD), could help jump-start a solid stream of passive…

While the better-than-expected GDP growth in the last quarter and declining inflationary pressures are raising optimism, macro uncertainties remain. With interest rate hikes expected to continue, recession possibilities cannot be ruled out. Therefore, fundamentally sound dividend-paying stocks, AbbVie (ABBV), Gilead Sciences (GILD), and Sisecam Resources (SIRE), could be worth investing…

Amid rising demand and government investments, the biotech industry is poised to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stock Gilead Sciences (GILD) might be a wise addition to your portfolio this January. However, Stoke Therapeutics (STOK) could be best avoided, given its bleak fundamentals.…